Clinical Trials Browser

Neoplasm Metastasis × Carboplatin × Gynecologic × Clear all

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07213804 2026-04-17

FRAmework-01

Phase 3 Recruiting

1,080 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Active not recruiting

94 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT06107868 2025-12-08

GyneRep

Phase 1 Active not recruiting

6 enrolled

Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Uterine Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03717415 2024-12-27

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

70 enrolled 24 charts

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms

NCT06413992 2024-05-14

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Phase 2 Recruiting

117 enrolled

Gynecologic

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms

NCT00993655 2023-08-28

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Phase 2 Completed

275 enrolled 13 charts

GynecologicThoracic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pleural Effusion, Malignant

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01445418 2019-10-22

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Phase 1 Completed

103 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01256268 2017-08-30

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Phase 1 Completed

24 enrolled

Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

Clinical Trials

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

FRAmework-01

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

GyneRep

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids